Independent Study Results In Japan Demonstrate 0% Breast Cancer Local Recurrence 5 Years Following Treatment With IceCure's ProSense, Adding To Continued Data Published Globally
Portfolio Pulse from Benzinga Newsdesk
An independent study in Japan showed 0% breast cancer local recurrence 5 years after treatment with IceCure's ProSense, demonstrating its potential as a standard treatment for early-stage breast cancer. The study, published in Breast Cancer journal, highlighted excellent cosmetic outcomes, high patient satisfaction, and improved quality of life post-cryoablation. IceCure's distribution partner in Japan, Terumo Corporation, plans to submit a regulatory clearance application for ProSense in H2 2024. IceCure expects to receive a total of $13.2 million from Terumo for exclusive distribution rights in Japan.
May 07, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IceCure's ProSense demonstrated 0% local recurrence in a Japanese study, with plans for regulatory submission in H2 2024 through Terumo, potentially boosting IceCure's revenue with $13.2 million from the partnership.
The positive study results and upcoming regulatory submission in Japan represent significant milestones for IceCure. The exclusive distribution agreement with Terumo, coupled with the expected financial inflows, could significantly impact IceCure's market position and financial health, likely leading to a positive short-term impact on its stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100